O
Ory Rouvio
Researcher at Soroka Medical Center
Publications - 9
Citations - 321
Ory Rouvio is an academic researcher from Soroka Medical Center. The author has contributed to research in topics: Immunology & Multiple myeloma. The author has an hindex of 5, co-authored 6 publications receiving 197 citations.
Papers
More filters
Journal ArticleDOI
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos,Fredrik Schjesvold,Fredrik Schjesvold,Meral Beksac,Roman Hájek,Katja Weisel,Hartmut Goldschmidt,Vladimir Maisnar,Philippe Moreau,Chang-Ki Min,Agnieszka Pluta,Wee Joo Chng,Martin Kaiser,Martin Kaiser,Sonja Zweegman,Maria-Victoria Mateos,Andrew Spencer,Shinsuke Iida,Gareth J. Morgan,Kaveri Suryanarayan,Zhaoyang Teng,Tomas Skacel,Antonio Palumbo,Antonio Palumbo,Antonio Palumbo,Ajeeta B Dash,Neeraj Gupta,Richard Labotka,S. Vincent Rajkumar,Daniel Bar,Alfredo Basso,Dorotea Fantl,Simon He,Neomi Horvath,Cindy Lee,Phillip Rowlings,Kerry Taylor,Tara Cochrane,Fiona Kwok,Sundreswran Ramanathan,Hermine Agis,Niklas Zojer,Alain Kentos,Fritz Offner,Jan Van Droogenbroeck,Ka Lung Wu,Angelo Maiolino,Gracia Martinez,Karla Zanella,Marcelo Capra,Sergio Eduardo Alonso Araujo,Evzen Gregora,Ludek Pour,Vlastimil Scudla,Ivan Spicka,Niels Abildgaard,Niels Holmark Andersen,Bo Amdi Jensen,Carsten Helleberg,Torben Plesner,Morten Salomo,Asta Svirskaite,Richard Delarue,Igor Wolfgang Blau,Aneta Schieferdecker,Veronica Teleanu,Markus Munder,Christoph Röllig,Han-Juergen Salwender,Stephan Fuhrmann,Katja Weisel,Jan Duerig,Matthias Zeis,Stefan Klein,Peter Reimer,Christian Schmidt,Christof Scheid,Karin Mayer,Martin Hoffmann,Markus Sosada,Athanasios Dimopoulos,Sosana Delimpasi,Mary-Christine Kyrtsonis,Achilleas Anagnostopoulos,Zsolt Nagy,Árpád Illés,Miklos Egyed,Zita Borbényi,Gabor Mikala,Najib Dally,Netanel Horowitz,Odit Gutwein,Anatoly Nemets,Iuliana Vaxman,Olga Shvetz,Svetlana Trestman,Rosa Ruchlemer,Arnon Nagler,Tamar Tadmor,Ory Rouvio,Meir Preis,Michele Cavo,Luca De Rosa,Pellegrino Musto,Anna Maria Cafro,Patrizia Tosi,Massimo Offidani,Alessandro Corso,Giuseppe Rossi,Anna Marina Liberati,Alberto Bosi,Kenshi Suzuki,Chiaki Nakaseko,Takayuki Ishikawa,Morio Matsumoto,Hirokazu Nagai,Kazutaka Sunami,Takaaki Chou,Koichi Akashi,Naoki Takezako,Shotaro Hagiwara,Hyeon Seok Eom,Deog-Yeon Jo,Jin Seok Kim,Jae Hoon Lee,Sung-Soo Yoon,Dok Hyun Yoon,Kihyun Kim,Mark-David Levin,Edo Vellenga,Monique C. Minnema,Anders Waage,Einar Haukås,Sebastian Grosicki,Andrzej Pluta,Tadeusz Robak,Herlander Marques,Rui Bergantim,Fernando Campilho,Wee Joo Chng,Yeow Tee Goh,Andrew McDonald,Bernado Rapoport,Miguel Angel Álvarez Rivas,Felipe de Arriba de la Fuente,Yolanda González Montes,Jesus Martin Sanchez,María-Victoria Mateos,Albert Oriol Rocafiguera,Laura Rosiñol,Jesús F. San Miguel,Jaime Pérez de Oteyza,Cristina Encinas,Adrian Alegre-Amor,Ana López-Guía,Per Axelsson,Kristina Carlson,Olga Stromberg,Markus Hansson,Cecile Hveding Blimark,Rouven Mueller,Chih-Cheng Chen,Ta-Chih Liu,Shang-Yi Huang,Po-Nan Wang,Thanyaphong Na Nakorn,Kannadit Prayongratana,Ali Ünal,Hakan Goker,Mehmet Sönmez,Sybiryna Korenkova,Aristeidis Chaidos,Heather Oakervee,Hamdi Sati,Reuben Benjamin,Ashutosh D. Wechalekar,Mamta Garg,Karthik Ramasamy,Gordon Cook,Andrew D Chantry,Matthew W Jenner,Francis K. Buadi,Robert Berryman,Murali Janakiram +183 more
TL;DR: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Yael C Cohen,Yael C Cohen,Mor Zada,Mor Zada,Shuang-Yin Wang,Chamutal Bornstein,Eyal David,Adi Moshe,Baoguo Li,Shir Shlomi-Loubaton,Moshe E. Gatt,Chamutal Gur,Chamutal Gur,Noa Lavi,Chezi Ganzel,Efrat Luttwak,Efrat Luttwak,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Oren Pasvolsky,Oren Pasvolsky,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky-Dolberg,Olga Shvetz,Meirav Laiba,Ofer Shpilberg,Najib Dally,Irit Avivi,Irit Avivi,Assaf Weiner,Ido Amit +34 more
TL;DR: In this article, a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) was conducted to study the molecular dynamics of MM resistance mechanisms.
Journal ArticleDOI
Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study
Drorit Merkel,Kalman Filanovsky,Anat Gafter-Gvili,Liat Vidal,Ariel Aviv,Moshe E. Gatt,Itay Silbershatz,Yair Herishanu,Ariela Arad,Tamar Tadmor,Najib Dally,Anatoly Nemets,Ory Rouvio,Aharon Ronson,Katrin Herzog-Tzarfati,Luiza Akria,Andrei Braester,Ilana Hellmann,Shay Yeganeh,Arnon Nagler,Ronit Leiba,Moshe Mittelman,Yishai Ofran +22 more
TL;DR: Patients with poor cytogenetics in whom AZA is prescribed despite low PLT count are particularly at high risk for infections and infection prophylaxis may be considered.
Journal ArticleDOI
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Yael C Cohen,Hila Magen,Hila Magen,Noa Lavi,Moshe E. Gatt,Evgeni Chubar,Nethanel Horowitz,Natalia Kreiniz,Tamar Tadmor,Svetlana Trestman,Roy Vitkon,Ory Rouvio,Olga Shvetz,Adir Shaulov,Tomer Ziv-Baran,Irit Avivi,Irit Avivi +16 more
TL;DR: Ixazomib-based combinations are efficacious and safe regimens in RRMM patients in the real-world setting, regardless to cytogenetic risk, with a PFS of 24 months comparable with clinical trial data.
Journal ArticleDOI
Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints
Yael C Cohen,Mor Zada,Moshe E. Gatt,Noa Lavi,Chezi Ganzel,Shuang-Yin Wang,Assaf Weiner,Guy Ledergor,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky Dolberg,Olga Shvetz,Ofer Shpilberg,Nagib Deli,Irit Avivi,Irit Avivi,Ido Amit +21 more
TL;DR: A high resolution molecular tool of massively-parallel single-cell RNA-sequencing (MARS-seq) calibrated for this trial aimed to identify gene expression signatures associated with clinical response and resistance, and compared them to NDMM and to healthy age and sex matched controls.